Medipharm Labs Corp. · TSX:LABS
Medipharm Labs — Conference Presentation (May 2021)
31 slides from Medipharm Labs's conference presentation, May 17, 2021
Slide 1: A Global GMP Platform Powering a Global Market
A Global GMP Platform Powering a Global Market TSX: LABS OTCQX: MEDIF May 17, 2021 FSE: MLZ
Slide 2: Disclaimer
Disclaimer May 17, 2021 – This presentation was prepared by management of MediPharm Labs Corp. (“MediPharm Labs”). The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that ma
Slide 3: MediPharm Labs is a trusted global leader
MediPharm Labs is a trusted global leader in pharma-quality, development and manufacturing of cannabis API and derivative products. TSX: LABS OTCQX: MEDIF FSE: MLZ 03 medipharmlabs.com
Slide 4: Our Strategy
Our Strategy Global supply chain and Capturing a larger segment Production agility and regulatory expertise - of the value chain - versatility – “multiple jurisdictions” “multiple products and API” “multiple customers” GMP Two GMP-certified Highly-skilled and diverse team CERTIFIED facilities in Can
Slide 5: Purposeful Execution of a Visionary Strategy
Purposeful Execution of a Visionary Strategy 2021+ Execution and Expansion 2020 2015-2018 2019 Transition Implementation Foundation Establish Pharmaceutical Strategy Signed 12+ bulk supply clients Achieved GMP certification status for including US markets Australian facility Obtained 1st Health Cana
Slide 6: Pharma-Canna Opportunity
Pharma-Canna Opportunity February 3, 2021 – Jazz Pharmaceuticals to acquire GW for $220.00 per Share for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. GW created Epidiolex, the first FDA-approved cannabinoid available for prescription in the U.S. Big Pharma is partnering wit
Slide 7: First-of-Its-Kind Pharmaceutical Partnership
First-of-its-Kind Pharmaceutical Partnership 125 years of history, German-based with Trusted global cannabis API and derivative products presence in 120 countries supplier and manufacturer, - 2019 revenues of €2.6B headquarters in Canada and Australia TSX: LABS OTCQX: MEDIF FSE: MLZ 07 medipharmlabs
Slide 8: Exclusive Partnership Agreement
STA + Exclusive Partnership Agreement MediPharm enters first-of-its-kind partnership with STADA, a European MediPharm will provide STADA will be responsible leader in generic pharmaceuticals, GMP certified medical for marketing and education consumer healthcare, and specialty cannabis products for u
Slide 9: STADA Partnership Reveals German Opportunity
STADA Partnership Reveals German Opportunity 75% Germany’s share of the European medical € 175M Medical cannabis sales in 2020 320KScripts 320,000 medical cannabis patient scripts in 2020 cannabis industry Only 1 in 10 German pharmacies provide cannabis products, German still supply € 7.5B Expected
Slide 10: Future Catalyst: Pharma Drivers
Future Catalyst: Pharma Drivers Further legalization of medical cannabis will continue to challenge Big Pharma’s bottom 80% In a survey of more than 1,300 consumers, 11% Average prescriptions for qualifying conditions line as consumer confidence in about 80% had used cannabis as a substitute for saw
Slide 11: Two-Country GMP Certification
Two-Country GMP Certification Our purpose-built facilities, to EU-GMP standards in both Canada and Australia, TGA-GMP use best-in-class technology and are • Canadian TGA-GMP achieved in December 2019 managed and operated by an expert team • Australian TGA-GMP achieved in May 2019 • TGA GMP recognize
Slide 12: Our Products & Service Solutions
Our Products & Service Solutions CONTRACT RESEARCH & PRODUCT DEVELOPMENT MANUFACTURING DEVELOPMENT Global Manufacturing Regulatory API, Finished Formulated Products Health Canada Research Licence Expertise Distribution Go-To Source of API Testing Tech Transfer IP Development via Clinical Trials Expe
Slide 13: Product Development & Formulation
Product Development & Formulation Pharmaceutical Project Creating Efficiencies Knowledge Management & Optimizing Processes Global Regulatory Marketing & Expertise Product Design TSX: LABS OTCQX: MEDIF FSE: MLZ 13 medipharmlabs.com
Slide 14: End-to-End Contract Manufacturing & Distribution
End-to-End Contract Manufacturing & Distribution GMP PHARMA-QUALITY CO2 EXTRACTION GMP CERTIFIED PRODUCTION AGILITY & TECH GLOBAL SUPPLY SOLUTIONS METHOD FACILITIES TRANSFER CHAIN Pharma-quality cannabis extraction MediPharm Labs uses a CO2 Our facilities in Australia and Canada are Wide-ranging pro
Slide 15: End-to-End White Label Manufacturing
End-to-End White Label Manufacturing Expanded Product Range & Production Versatility Manufacturing multiple finished products for some of the biggest names in the cannabis, health, wellness, food and beverage industries today. Our existing product range includes oils, vapes, soft- gels, hard capsule
Slide 16: Our Client Partners
Our Client Partners TSX: LABS OTCQX: MEDIF FSE: MLZ 16 medipharmlabs.com
Slide 17: MediPharm Labs Family of Branded Products
MediPharm Labs Family of Branded Products The result of manufacturing expertise, brand recognition, and consumer demand, MediPharm Labs created and launched our own product line in 2019. Available in medical and adult- use channels. TSX: LABS OTCQX: MEDIF FSE: MLZ 17 medipharmlabs.com
Slide 18: Canada HQ Australia HQ
Canada HQ • HQ in Barrie, Ontario • 70,000 sq ft facility • TGA GMP Certified • Global export and distribution of product • EU GMP Pending Canada Australia Europe Australia HQ LATAM • HQ in Victoria, Australia • 10,000 sq ft facility • TGA GMP Certified, PICs member Targeted Expansion nation • Globa
Slide 19: Sales by Targeted Region
Sales by Targeted Region Canada Australia Europe LATAM Other 2019 2020 2025* * Potential growth in multiple jurisdictions TSX: LABS OTCQX: MEDIF FSE: MLZ 19 medipharmlabs.com
Slide 20: Sales by Service Offering Projected
Sales by Service Offering Projected 2025* 2020 2019 Bulk Wholesale Contract Manufacturing and branded products (White Label) ** Potential growth in multiple jurisdictions TSX: LABS OTCQX: MEDIF FSE: MLZ 20 medipharmlabs.com
Slide 21: Future Plans & Upcoming Catalysts
Future Plans & Upcoming Catalysts Multiple Customers Multiple Products Multiple Jurisdictions Expand pharmaceutical and Clinical trials and expansion of European Expansion, APAC, and international export supply addressable medicinal and wellness LATAM pharmaceutical expansion agreements markets Furt
Slide 22: Capital Structure & Ownership
Capital Structure & Ownership Capital Structure (as at March 31, 2021)* Cash Position Number Cash Position (as at March 31, 2021) $42.1 million Security (millions) Bought Deal Financing (Completed March 5, 2021)* $33.3 million Common Shares(1) 257.9 Share Price Options (1) 10.7 Convertible Note: Mar
Slide 23: Q&A
Q&A TSX: LABS OTCQX: MEDIF FSE: MLZ 23 medipharmlabs.com
Slide 24: Appendix
Appendix TSX: LABS OTCQX: MEDIF FSE: MLZ 24 medipharmlabs.com
Slide 25: Our History
Our History MediPharm Labs was founded in 2015 Pursued regulatory goals with a focus on supplying pharma- with 1st Health Canada quality cannabis extraction products extraction-only licence and and derivatives formulated by a team of 1st purpose-built GMP scientists and pharmaceutical experts. manuf
Slide 26: Operational Business Model
Operational Business Model FINISHED PRODUCT GMP IS DELIVERED TO PLATFORM PARTNERS DRIED CANNABIS IS PURCHASED FROM QUALIFIED LICENCE HOLDERS GMP CERTIFIED ORGANIC CERTIFIED • Licensed producers • CPG • Research and Development • Pharmaceutical applications PROCESSING DISTRIBUTION PACKAGING TSX: LABS
Slide 27: Producing Extraction Inputs
Producing Extraction Inputs PRIVATE LABEL / WHOLESALE ADVANCED DERIVATIVE PRODUCTS ACTIVE PHARMACEUTICAL INGREDIENTS CRUDE RESIN CANNABINOID DISTILLATE CANNABINOID ISOLATES 70-80% 80-95% 98%+ Vapes Topicals Active Pharmaceutical Ingredients (API) THC CBD Bottled Capsules Edible Beverage Inputs CBN T
Slide 28: MediPharm Labs Branded Product Family
MediPharm Labs Branded Product Family CBD25:5 Release Formula CBD50 Plus Formula CBD25 Regular Formula Available in select private retail stores as well as Medical Cannabis by Shoppers, Saskatchewan, BC, Alberta and Manitoba TSX: LABS OTCQX: MEDIF FSE: MLZ 28 medipharmlabs.com
Slide 29: Management Team
Management Team Keith Strachan Greg Hunter Warren Everitt President, Interim CEO, Co-Founder Chief Financial Officer Chief Executive Officer, Asia Pacific A healthcare business development expert, bringing A seasoned executive with over 20 years of experience Warren brings senior leadership in Asia
Slide 30: Board of Directors
Board of Directors Pat McCutcheon Chris Halyk Shelley Martin Chris Taves Founder and Chairman of the Board Independent Director Independent Director Independent Director Former President of Janssen Inc. (Canada) Former President of Nestlé Canada COO, BMO Capital Markets Miriam McDonald Dr. Paul Tam
Slide 31: For additional information, please contact:
@medipharmlabs For additional information, please contact: @medipharmlabs Keith Strachan President and Interim Chief Executive Officer @medipharmlabs Laura Lepore Vice President, Investor Relations /medipharm-labs investors@medipharmlabs.com +1 (416) 913-7425 x1525